Vischer with Mosanna Therapeutics on funding round
Vischer advised Mosanna Therapeutics in connection with its USD 80m Series A funding round.
Headquartered in Basel, Switzerland, the clinical-stage biotech company, is working on a nighttime nasal spray to treat obstructive sleep apnea (OSA).
The round
EQT Life Sciences and Pivotal bioVenture Partners led the capital round in question, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).
The Vischer team
Partner Matthias Staehelin led the Vischer team (corporate/M&A, pictured) and includes partner Nadia Tarolli (tax), managing associate Luzius Zumstein (corporate/M&A), associate Diego Anzante (tax) and senior associate Timothy Woodtli (corporate/M&A).
